×
Ardelyx EBIT 2013-2024 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ardelyx ebit from 2013 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Ardelyx EBIT 2013-2024 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ardelyx ebit from 2013 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$80.4B
Zoetis (ZTS)
$70.5B
Takeda Pharmaceutical (TAK)
$44.1B
Daiichi Sankyo, - (DSNKY)
$43.3B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.5B
Astellas Pharma (ALPMY)
$17.5B
Summit Therapeutics (SMMT)
$17B
United Therapeutics (UTHR)
$16.4B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.6B
Orion OYJ (ORINY)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Corcept Therapeutics (CORT)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Ionis Pharmaceuticals (IONS)
$5.2B
Grifols, S.A (GRFS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.2B
Hypermarcas (HYPMY)
$2.2B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Dyne Therapeutics (DYN)
$1.4B